Former US President Donald Trump has once again put Big Pharma in the crosshairs with a bold proposal aimed at making prescription drugs more affordable. The plan, which has sparked fierce debate, could force major pharmaceutical companies to lower prices—a move that critics argue may stifle innovation, while supporters claim it’s long overdue for struggling patients.
Trump’s Cost-Cutting Crusade
Trump’s latest push targets the soaring costs of life-saving medications, a key issue that has plagued American healthcare for years. His proposal suggests leveraging federal power to negotiate drug prices directly, a strategy that has drawn both praise and backlash.
Big Pharma’s Backlash
Pharmaceutical giants have warned that such measures could jeopardise research and development, potentially delaying breakthrough treatments. Industry lobbyists argue that high prices are necessary to fund innovation, but patient advocacy groups counter that profits are prioritised over accessibility.
Patients Caught in the Middle
For millions of Americans, the high cost of prescription drugs remains a daily burden. Stories of individuals rationing medication or skipping doses due to financial strain have fueled public outrage, adding pressure on policymakers to act.
What’s Next?
As the debate rages on, the question remains: can affordability and innovation coexist? With the 2024 election looming, Trump’s plan could become a central issue in the battle over healthcare reform.
